Get started
Author

Rebecca Lyon

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
2022 · Alasdair P S Munro, Shuo Feng, et al. · The Lancet Infectious Diseases · 168
PDF
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
2021 · Saye H Khoo, Richard Fitzgerald, et al. · Journal of Antimicrobial Chemotherapy · 115
PDF
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
2022 · Saye H Khoo, Richard FitzGerald, et al. · The Lancet Infectious Diseases · 80
PDF
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
2022 · I’ah Donovan-Banfield, Rebekah Penrice-Randal, et al. · Nature Communications · 35
PDF
An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2
2021 · Lauren E. Walker, Richard FitzGerald, et al. · Clinical Pharmacology & Therapeutics · 25
PDF
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection
2022 · Richard FitzGerald, Laura Dickinson, et al. · Clinical Infectious Diseases · 24
PDF
An investigation into why patients do not attend for out-patient radiology appointments
2005 · Rebecca Lyon, Pauline J. Reeves · Radiography · 17
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter
2021 · Gareth O. Griffiths, Richard FitzGerald, et al. · Trials · 16
PDF
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study
2026 · Tim Rowland, Richard FitzGerald, et al. · Clinical Pharmacology & Therapeutics · 4
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
2026 · Saye H Khoo, Richard FitzGerald, et al. · Journal of Antimicrobial Chemotherapy · 1
Pharmacokinetics of the inactive favipiravir metabolite, favipiravir hydroxide (M1), as a proxy for establishing metabolic activity in patients receiving intravenous favipiravir for treatment of SARS‐CoV‐2 infection
2025 · E. Challenger, L. Else, et al. · British Journal of Clinical Pharmacology · 1
PDF
Bridging care and research: outcomes from a hospital‑based asthma optimisation clinic
2026 · Maria Puthoor, Rachel Burton, et al. · European Respiratory Journal
A phase I double-blind, placebo-controlled (Part B only), randomised trial to evaluate the safety, tolerability, and pharmacokinetics of single dose in fed state, and repeat doses of DNDI-6899 in healthy participants
2026 · Michelle Tetlow, Francois Simon, et al. · Wellcome Open Research
Implementing and evaluating a development pathway for early-career research nurses
2025 · Arun Vamadevan, Rebecca Lyon, et al. · Nursing Management
Pharmacokinetics of nitazoxanide in plasma separation cards from patients with SARS‐CoV‐2: AGILE CST‐3a/b
2025 · B. Thompson, L. Else, et al. · British Journal of Clinical Pharmacology
PDF
Works count: 15
Citation count: 486
H-index: 8
I10-index: 8
Year
Topic
Type